Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. - Wikidata - wikimedia - TriplyDB

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.

http://www.wikidata.org/entity/Q33688564

about

The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data.

P2860

Q42363904-B98BEED7-B5A1-474B-A4F8-910D3A5DB137

P2860

Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.

http://www.wikidata.org/entity/Q33688564

description

2017 nî lūn-bûn

@nan

2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Immunohistochemical Ki67 after ...... s reliably as genomic markers.

@ast

Immunohistochemical Ki67 after ...... s reliably as genomic markers.

@en

type

label

Immunohistochemical Ki67 after ...... s reliably as genomic markers.

@ast

Immunohistochemical Ki67 after ...... s reliably as genomic markers.

@en

prefLabel

Immunohistochemical Ki67 after ...... s reliably as genomic markers.

@ast

Immunohistochemical Ki67 after ...... s reliably as genomic markers.

@en

P1433

Q33688564-E1FCDAB2-D808-4AC4-8E3F-80DFC2A8DA02

P1476

Q33688564-F478B7A7-95E3-4719-83D0-A9D7490EB7F8

P2093

Q33688564-14B3C1EE-531B-429B-B666-19EDD3D47272

Q33688564-2380D3A7-B3F5-4439-9993-770575E22C66

Q33688564-2B11AAB0-ED67-4BE4-9230-6793B9C07D79

Q33688564-4317EDA1-697D-4C97-99DF-7C26F4133ABC

Q33688564-54602A72-0CBA-4C9A-BA8B-1A4CA0523C79

Q33688564-5E17F26D-F444-4D50-AC24-EB9A590485A3

Q33688564-687051ED-57F4-4044-B7BA-89873E4378A0

Q33688564-AD480DF4-3BB1-47D4-9B0E-3A3117522D87

Q33688564-B9C68080-986B-4424-A322-F7BBB324EFEB

Q33688564-BA9334CE-A48B-466B-A145-168C64338298

P2860

Q33688564-12951FF0-6B1F-46BA-856C-0F4A6FB7188E

Q33688564-1F2BC7CB-13B9-45F5-930C-CC6630F42453

Q33688564-3EA912C7-396E-4186-85BA-4C738EFA169E

Q33688564-7AFA39CE-E5BD-4F52-9BBA-45A32D60448B

Q33688564-84202E67-DBCD-4671-B6E9-C2071F26E38A

Q33688564-B1603FAD-4EE9-4FF3-BDCC-DFAE5BF7F151

Q33688564-B71B7F00-7286-4C39-9203-2B18249D565B

Q33688564-C7E31841-5CF8-473D-8588-FF2A8F38ED82

Q33688564-D66D1601-0FCC-4AE8-ACC9-A11BCE82E8B3

Q33688564-EC855BEE-703C-42F9-861B-EA29119EF6DC

P304

Q33688564-A60EF75A-A078-4330-B0CE-6020823930B0

P31

Q33688564-8B077A0E-37C6-483C-B846-B7D2F0FF9DE4

P356

Q33688564-4D1D76DC-66D7-413C-83A3-1B337F580E72

P407

Q33688564-40CCC670-F8B7-4299-B1E4-1B38141E6DF1

P433

Q33688564-74DD9D4D-87E9-45A3-85C1-3FDB5B2B5187

P478

Q33688564-2F3935EB-6ACC-4901-90D0-5EA082E4B166

P577

Q33688564-60440116-8A48-4167-A731-450D395BCB3B

P698

Q33688564-19E000A5-A441-4F93-B893-B598BF49C471

P921

Q33688564-325B2F2D-A7E1-4C1C-A0A7-22413347263E

P932

Q33688564-A8BF6122-29A0-4D23-9716-A04703F60B3F

P356

ONCOTARGET.15385

P1433

P1476

Immunohistochemical Ki67 after ...... s reliably as genomic markers.

@en

P2093

Balazs Gyorffy

http://www.w3.org/2001/XMLSchema#string

Hiroyoshi Doihara

http://www.w3.org/2001/XMLSchema#string

Junji Matsuoka

http://www.w3.org/2001/XMLSchema#string

Mariko Kochi

http://www.w3.org/2001/XMLSchema#string

Masako Omori

http://www.w3.org/2001/XMLSchema#string

Naoki Niikura

http://www.w3.org/2001/XMLSchema#string

Naruto Taira

http://www.w3.org/2001/XMLSchema#string

Tadahiko Shien

http://www.w3.org/2001/XMLSchema#string

Takayuki Iwamoto

http://www.w3.org/2001/XMLSchema#string

Takayuki Motoki

http://www.w3.org/2001/XMLSchema#string

P2860

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

An international Ki67 reproducibility study.

Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.

P304

26122-26128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.15385

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28412725

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

5432244

http://www.w3.org/2001/XMLSchema#string